RevenueNet IncomeP/EP/SEBITDividendStocksMarket capitalizationDebtLiabilitiesEquityAAQSEmployeesROEROAROCE

Regeneron Pharmaceuticals Stocks 2024

Regeneron Pharmaceuticals Stocks

113.7 M

Regeneron Pharmaceuticals Dividend yield

Ticker

REGN

ISIN

US75886F1075

WKN

881535

In 2024, Regeneron Pharmaceuticals had 113.7 M outstanding stocks, a 0% change from the 113.7 M stocks in the previous year.

The Regeneron Pharmaceuticals Stocks history

YEARNUMBER OF STOCKS (undefined USD)
2029e113.7
2028e113.7
2027e113.7
2026e113.7
2025e113.7
2024e113.7
2023113.7
2022114
2021112
2020115
2019115
2018115
2017116
2016116
2015115
2014113
2013111
2012115
201191
201083
200980
200879
200766
200658
200556
200456

Regeneron Pharmaceuticals Aktienanalyse

What does Regeneron Pharmaceuticals do?

Regeneron Pharmaceuticals Inc. is an American biotechnology company founded in 1988 by Leonard Schleifer. The company is headquartered in Tarrytown, New York and employs approximately 8,500 people worldwide. Regeneron is known for its research in the areas of cancer therapies, eye diseases, and asthma. Regeneron operates a business model based on the research and development of biotechnological drugs. The company invests heavily in research and seeks new compounds that can fight inflammation and cancer. Regeneron develops its products using the reverse transcriptase polymerase chain reaction (RT-PCR), a method for amplifying RNA molecules into DNA. This method allows for the rapid production and analysis of large amounts of genetic material. The company is divided into several divisions, including ophthalmology, inflammatory diseases, oncology, and neurology. Regeneron also produces a wide range of biopharmaceutical products, including antibodies, interleukins, enzymes, and fusion proteins. One of Regeneron's most popular products is EYLEA (Aflibercept), a medication used to treat retinal diseases such as age-related macular degeneration. EYLEA has been on the market since 2011 and has proven to be highly effective. The medication is a blockbuster for Regeneron and accounts for a significant portion of its product revenue. Another important product from Regeneron is Dupixent (Dupilumab), a medication used to treat atopic dermatitis and severe asthma. The medication has been on the market since 2017 and has quickly established itself as a key treatment for asthma. Dupixent is produced in collaboration with Sanofi. Regeneron has also conducted promising research in the field of oncology. The company has developed a range of cancer therapies that are in the clinical phase of development. One example is the antibody Libtayo, which is used to treat squamous cell carcinomas. In its recent history, Regeneron has played a major role in the research and development of antibodies for the treatment of COVID-19. Regeneron was the first company to receive funding from the US government for the development of an antibody cocktail for the treatment of COVID-19. The medication, consisting of the antibodies Casirivimab and Imdevimab, was granted emergency use authorization by the US Food and Drug Administration in November 2020. Regeneron also has an extensive partnership with pharmaceutical company Sanofi. The two companies have jointly developed products such as Praluent (Alirocumab), a medication used to lower cholesterol levels, and Kevzara (Sarilumab), a medication used to treat rheumatoid arthritis. Overall, in recent years, Regeneron has built a strong position as a leading biotechnology company. The company has an impressive product pipeline and has developed a wide range of important medications. Regeneron continues to work on the development of new therapies and has the potential to play a significant role in the biotechnology industry in the coming years. Regeneron Pharmaceuticals ist eines der beliebtesten Unternehmen auf Eulerpool.com.

Regeneron Pharmaceuticals revenue by segment

In the annual report of the Regeneron Pharmaceuticals share (US75886F1075, 881535, REGN), it breaks down its revenues into 1 segments: 1. Medicines. The Regeneron Pharmaceuticals stock (WKN: 881535, ISIN: US75886F1075, Ticker Symbol: REGN) is a leading investment for investors interested in participating in the Health Care sector.

Stocks Details

Evaluating Regeneron Pharmaceuticals's Shares Outstanding

Regeneron Pharmaceuticals's shares outstanding refer to the total number of shares that are currently held by all its shareholders, including institutional investors and restricted shares held by the company’s officers and insiders. The number of shares outstanding is crucial in determining the company's market capitalization and is used by investors to assess the company’s size, financial health, and investment potential.

Year-to-Year Comparison

Tracking the changes in Regeneron Pharmaceuticals’s shares outstanding over the years can provide investors with insights into the company's financial strategies and market valuation. An increase in shares outstanding can result from actions like issuing new shares, while a decrease can result from buybacks.

Impact on Investments

For investors, understanding Regeneron Pharmaceuticals’s shares outstanding is essential for evaluating its earnings per share (EPS) and market valuation. A change in the number of shares outstanding can impact the EPS, which is a significant driver of stock prices and investor decisions.

Interpreting Changes in Shares Outstanding

Variances in Regeneron Pharmaceuticals’s shares outstanding can signal shifts in the company’s financial strategy. An increase may dilute the EPS and share value, indicating potential fundraising or acquisitions. Conversely, a decrease, often due to share buybacks, can enhance share value and indicate the company’s confidence in its financial performance.

Frequently Asked Questions about Regeneron Pharmaceuticals Stock

How many stocks are there of Regeneron Pharmaceuticals?

The current number of stocks of Regeneron Pharmaceuticals is 113.7 M undefined.

What does Number of Shares / OutstandingShares mean?

The outstanding shares (or issued shares) of Regeneron Pharmaceuticals are the total number of shares issued and actively held by shareholders - both external investors and company insiders. However, these must be actual shares. may grant stock options to executives that can be converted into shares.

How has the number of shares of Regeneron Pharmaceuticals evolved in recent years?

The number of shares of Regeneron Pharmaceuticals has increased by 0% gestiegen compared to last year.

What does the number of shares mean for investors?

The number of shares outstanding is used to calculate key metrics such as a company's market capitalization, earnings per share (EPS), and cash flow per share (CFPS). The number of outstanding shares of a company is not static and can fluctuate greatly over time.

Why does the number of stocks fluctuate?

There are various factors that can lead to a change. Regeneron Pharmaceuticals as a company can issue new shares, carry out stock splits or reverse splits.

Does the number of shares have an impact on the performance of Regeneron Pharmaceuticals?

There is no tangible long-term evidence or study that stocks with a certain number of shares (regardless of Mega/Large/Mid/Small Cap) would yield significantly higher returns than others. There are occasional small studies (limited number of stocks, short investment period) that certain classes outperform or have higher risk, but none of them are 1. conclusive (cause-effect is unclear, experiment is not repeatable) or 2. generalizable (generalization is not possible due to small sample size and time period).

How much dividend does Regeneron Pharmaceuticals pay?

Over the past 12 months, Regeneron Pharmaceuticals paid a dividend of . This corresponds to a dividend yield of about . For the coming 12 months, Regeneron Pharmaceuticals is expected to pay a dividend of 0 USD.

What is the dividend yield of Regeneron Pharmaceuticals?

The current dividend yield of Regeneron Pharmaceuticals is .

When does Regeneron Pharmaceuticals pay dividends?

Regeneron Pharmaceuticals pays a quarterly dividend. This is distributed in the months of .

How secure is the dividend of Regeneron Pharmaceuticals?

Regeneron Pharmaceuticals paid dividends every year for the past 0 years.

What is the dividend of Regeneron Pharmaceuticals?

For the upcoming 12 months, dividends amounting to 0 USD are expected. This corresponds to a dividend yield of 0 %.

In which sector is Regeneron Pharmaceuticals located?

Regeneron Pharmaceuticals is assigned to the 'Health' sector.

Wann musste ich die Aktien von Regeneron Pharmaceuticals kaufen, um die vorherige Dividende zu erhalten?

To receive the latest dividend of Regeneron Pharmaceuticals from 4/26/2024 amounting to 0 USD, you needed to have the stock in your portfolio before the ex-date on 4/26/2024.

When did Regeneron Pharmaceuticals pay the last dividend?

The last dividend was paid out on 4/26/2024.

What was the dividend of Regeneron Pharmaceuticals in the year 2023?

In the year 2023, Regeneron Pharmaceuticals distributed 0 USD as dividends.

In which currency does Regeneron Pharmaceuticals pay out the dividend?

The dividends of Regeneron Pharmaceuticals are distributed in USD.

Stock savings plans offer an attractive way for investors to build wealth over the long term. One of the main advantages is the so-called cost-average effect: by regularly investing a fixed amount in stocks or stock funds, you automatically buy more shares when prices are low, and fewer when they are high. This can lead to a more favorable average price per share over time. In addition, stock savings plans allow small investors access to expensive stocks, as they can participate with small amounts. Regular investment also promotes a disciplined investment strategy and helps to avoid emotional decisions, such as impulsive buying or selling. Furthermore, investors benefit from the potential appreciation of the stocks as well as from dividend distributions, which can be reinvested, enhancing the compounding effect and thus the growth of the invested capital.

The Regeneron Pharmaceuticals stock can be added to a savings plan with the following providers: Trade Republic, ING, Scalable Capital and Consorsbank

Andere Kennzahlen von Regeneron Pharmaceuticals

Our stock analysis for Regeneron Pharmaceuticals Revenue stock includes important financial indicators such as revenue, profit, P/E ratio, P/S ratio, EBIT, as well as information on dividends. We also assess aspects such as stocks, market capitalization, debt, equity, and liabilities of Regeneron Pharmaceuticals Revenue. If you are looking for more detailed information on these topics, we offer comprehensive analyses on our subpages.